Kumar Simit, Bandyoapdhyay Maitreyi, Chatterjee Mitali, Mukhopadhyay Prabir, Poddar Sumon, Banerjee Parthajit
Department of Microbiology, R.G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
Avicenna J Med. 2014 Jan;4(1):13-6. doi: 10.4103/2231-0770.127416.
Linezolid provides high rates of the clinical cure and microbiological success in complicated infections due to Enterococcus spp., including vancomycin-resistant Enterococcus faecium. However, the emergence of resistance during linezolid treatment has been reported for clinical strains of Enterococcus, which is alarming given the fact that, this leaves the clinician with very few treatment options. We report the first case of linezolid resistant Enterococcus faecium from India, which was isolated from the blood culture of a hypoglycemic encephalopathy patient. There have been previous reports of linezolid resistant enterococci from different parts of the world, with minimum inhibitory concentration (MIC) ranging from 16 to 64 μg/mL and most of them were associated with vancomycin resistance but the isolate reported over here had an MIC of 1024 μg/mL and interestingly was sensitive to vancomycin.
利奈唑胺在治疗由肠球菌属引起的复杂感染（包括耐万古霉素的屎肠球菌）时，具有较高的临床治愈率和微生物清除率。然而，已有报道称利奈唑胺治疗期间肠球菌临床菌株出现了耐药性，鉴于此，临床医生的治疗选择非常有限，这令人担忧。我们报告了印度首例耐利奈唑胺的屎肠球菌，该菌株从一名低血糖脑病患者的血培养物中分离得到。此前世界各地已有耐利奈唑胺肠球菌的报道，其最低抑菌浓度（MIC）为16至64μg/mL，且大多数与万古霉素耐药相关，但此处报告的分离株MIC为1024μg/mL，有趣的是它对万古霉素敏感。
